bit.bio
bit.bio is an award-winning human synthetic biology company whose mission is to code cells for novel cures. They have developed an end-to-end platform for the creation of any human cell type. With their cutting-edge and patent-protected opti-ox™ precision cell programing technology, bit.bio can deterministically program human induced pluripotent stem cells (iPSCs) into a chosen cell identity with unprecedented biological consistency at an industrial scale and approximately 10 times faster than conventional methods. Their platform has the potential to unlock a new generation of medicines.
Latest bit.bio Content
App Note / Case Study
Precision Reprogrammed iPSC Models for High-Throughput Drug Discovery
This app note delves into the role of TDP-43 protein aggregates in the disease's progression. Charles River Laboratories and bit.bio present a breakthrough in ALS research with genetically matched ioGlutamatergic Neurons, providing a crucial in vitro model.
Webinar
Uncovering the Glioma Microenvironment With In Vitro Neuronal Models
On-Demand
In this webinar, you’ll hear from Dr. Brian Gill about his research into neuron–glioma interactions and how they contribute to seizures and tumoral growth.
Online Event
Innovations in Disease Modeling 2024
On-Demand
Explore the tools and techniques being used to study diseases in the lab. Discover how advances in cell culture and disease modeling are supporting diagnostic and therapeutic development.
Industry Insight
The Pathology of Proteins: A Tangled Tale of Alzheimer's
Explore the current understanding from the scientific literature on how protein misfolding, mislocalization and malfunction can lead to Alzheimer's disease.
Video
Revolutionizing In Vitro Disease Models With iPSC Reprogramming Technology
In this Teach Me in 10, we are joined by Dr. Will Bernard to get a primer on the latest innovations in in vitro human cell technology.
Video
Precision Reprogramming iPSCs To Generate a Source of Defined, Scalable Human Cells
See how bit.bio's platform uses opti-ox technology to consistently convert stem cells into defined human cells.
Poster
Discover a New Approach to Modeling Neurodegeneration
This poster demonstrates how a novel, precise and highly controlled iPSC reprogramming technology overcomes these limitations and enables the generation of mature cell types and isogenic models of neurodegenerative disease.
Poster
Optimized Human iPSC-Derived Sensory Neurons for Pain and Neuropathy Research
Many promising drugs which show efficacy in animal models have failed in the clinic due to interspecies variance in nociception mechanisms. Hence, consistent, scalable human in vitro models are required to accelerate potential therapeutics to the clinic.
Poster
Generating Pure, Consistent GABAergic Neurons From hiPSCs
While animal models and primary cells remain valuable resources, neuronal drug development faces many challenges. Not least, the variability and inaccuracy of traditional model systems can result in the failure to translate data into successful clinical trials.
Poster
Functional, Reprogrammed Microglia To Study Neurodegeneration
Microglia play key roles in neurogenesis, synaptic remodeling, and are the first responders to infection in the brain. Hence, disease-relevant cell models are key to the success of neuroimmune and neurodegeneration research.
Advertisement
